– Phase 1b dose escalation clinical trial confirmed safety, preliminary efficacy and identified the recommended phase 2 dose of onvansertib- Complete response (CR + CRi) achieved in 5 of 21 patients treated with onvansertib in combination with decitabi… […]
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Debut Biotechnology, a startup located in San Diego, California, has exclusively licensed two inventions from the University of California, Irvine (UCI) that will allow continuous manufacturing in the pharma… […]
SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, tod… […]
Report seeks to foster creative thinking and new approaches to addressing obstacles to patients getting the answers and care they need
ALISO VIEJO, Calif., Sept. 18, 2019 /PRNewswire/ — The rapid progress of technology is creating an opportunity to … […]
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The st… […]
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has named AnaBios the recipient of a grant to further develop its unique drug discovery platform utilizing muscle cells from the human heart (cardiomyocytes). Fu… […]
$1.86 Million Over Two Years to Develop Device for Isolating Exosomes
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health, announced today that the N… […]
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two ind… […]
Company expands pipeline of innovative therapies for immunocompromised patients
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening dis… […]
– Phase III FeDeriCa Study Met Primary Endpoint of Non-inferiority — New Subcutaneous Fixed-dose Combination Significantly Reduced Administration Time — Data to be Submitted to Health Authorities including the U.S. Food and Drug Administration and Eu… […]
Copyright © 2019 San Diego Biotechnology Network (DBA of Comprendia. LLC)
